계명대학교 의학도서관 Repository

Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)

Metadata Downloads
Author(s)
Sung-Hoon JungJe-Jung LeeWon Seog KimWon-Sik LeeYoung Rok DoSung Yong OhMin Kyoung KimYeung-Chul MunHo-Jin ShinJae-Yong KwakHye Jin KangJong Ho WonJung Hye KwonEunkyung ParkCheolwon SuhDeok-Hwan Yang
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
European Journal of Haematology
Issued Date
2015
Volume
94
Issue
6
Abstract
This study aimed to determine the objective response, toxicity, and clinical outcome of weekly rituximab
consolidation after four cycles of R-CHOP21 in very elderly patients with DLBCL. A prospective, multi-
institutional phase II trial was conducted on patients with previously untreated CD20
+
DLBCL who were
older than 70 yr. Patients were treated with four cycles of R-CHOP21 followed by weekly consolidation
with rituximab (375mg/m
2
, four times infusion) (NCT01181999). We also compared the clinical outcomes
with an historical case-matched control group treated conventionally with six cycles of R-CHOP21. A total
of 51 patients with newly diagnosed DLBCL were enrolled at 15 institutes between June 2010 and
September 2013. The median age was 76 yr (range: 70–89). Forty-one of the 51 patients completed the
planned rituximab consolidation (R-consolidation). The overall response rate was 78.4%, comprising 74.5%
with a complete response and 3.9% with a partial response. After a median follow-up of 20.3 months, 2-
yr progression-free survival and overall survival were 63.9% and 68.7%, respectively. No serious toxicities
were reported during rituximab consolidation. Weekly rituximab consolidation following four cycles of R-
CHOP21 resulted in an acceptable response with high tolerability and could be a good compromise
between efficacy and safety for elderly patients with DLBCL.
Key words elderly; diffuse large B-cell lymph oma; rituximab consolidation
Correspondence Deok-Hwan Yang, MD, PhD, Department of Hematology-Oncology, Chonnam National University Hwasun Hospital,
322 Seoyangro, Hwasun, Jeollanamdo 519-763, Korea. Tel: 82-61-379-7636; Fax: 82-61-379-7628; E-mail: drydh1685@hotmail.com
Accepted for publication 30 September 2014
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine
Citation
Sung-Hoon Jung et al. (2015). Weekly rituximab consolidation following four cycles of
R-CHOP induction chemotherapy in very elderly patients
with diffuse large B-cell lymphoma: Consortium for
improving survival of lymphoma study (CISL). European Journal of Haematology, 94(6), 504–510. doi: 10.1111/ejh.12459
Type
Article
ISSN
0902-4441
Source
http://dx.doi.org.proxy.dsmc.or.kr/10.1111/ejh.12459
DOI
10.1111/ejh.12459
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35655
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.